Since the 1950s, plastic production has skyrocketed. Various environmental and human activities are leading to the formation and accumulation of microplastics (MPs) in aquatic and terrestrial ecosystems, causing detrimental effects on water, soil, plants, and living creatures. Wastewater treatment plants (WWTPs) are one of the primary MP management centers meant to check their entry into the natural systems. However, there are considerable limitations in effectively capturing, detecting, and characterizing these MPs in the inlet and outlet of WWTPs leading to “unaccounted MPs” that are eventually discharged into our ecosystems. In order to assess the holistic picture of the MPs’ distribution in the ecosystems, prevent the release of these omitted MPs into the environment, and formulate regulatory policies, it is vital to develop protocols that can be standardized across the globe to accurately detect and account for MPs in different sample types. This review will cover the details of current WWTP adoption procedures for MP management. Specifically, the following aspects are discussed: (i) several processes involved in the workflow of estimating MPs in the outlet of WWTPs; (ii) key limitations or challenges in each process that would increase the uncertainty in accurately estimating MPs; (iii) favorable recommendations that would lead to the standardization of protocols in the workflow and facilitate more accurate analysis of MPs; (iv) research opportunities to tackle the problem of ‘missing MPs’; and (v) future research directions for the efficient management of MPs. Considering the burgeoning research interest in the area of MPs, this work would help early scientists in understanding the current status in the field of MP analysis in the outlet of WWTPs.

The effective management of the coronavirus disease 2019 (COVID-19) pandemic depends on the bedrock of rapid and accurate testing to enable promptness in quarantining, contact tracing, epidemiologic characterization, evaluating vaccine response, and strategic decision-making. In this context, point-of-care (POC) tests are of utmost importance as they facilitate rapid and decentralized testing without much instrumentation and technical expertise. The review describes the current status of POC COVID-19 testing in three broad categories: molecular, antigen, and antibody. The advantages, limitations, and adaption of each of the three types of POC tests are discussed while highlighting their clinical impact in real-world settings. The role of POC testing for COVID-19 screening, diagnosis, and surveillance has been highlighted, focusing on recent advances in the field. The difference between POC and at-home tests is discussed while elaborating on the necessity for the latter. A spotlight on the impact of variants on the performance of COVID-19 tests is provided. The clinical impact of POC testing in hospitals with regard to improving therapeutic options, patient flow, enhancing the infection control measures, and early recruitment of patients into clinical trials is discussed. Finally, the future perspectives that will aid the research community in the development of POC tests for COVID-19 or any infectious disease, in general, are presented. Overall, we believe this review can benefit the research community as it (i) presents a comprehensive understanding of current COVID-19 POC testing methods (ii) highlights features required to transform the current tests developed during the past year as POC diagnostics, and (iii) provides insights to address the unmet challenges in the field. Keywords COVID-19 SARS-CoV-2 Point-of-care Testing Diagnosis Screening Surveillance Variants At-home

RNAi therapeutics possess the potential to cure many uncurable human diseases. For instance, RNAi therapeutics using liposomes showed remarkable survival benefits in patients with liver diseases. However, the extension of liposomes to deliver RNA to cure other ailments has largely been unsuccessful. Therefore, researchers are focusing on designing and testing different combinations of materials for versatile RNA delivery applications. Yet, an efficient and safe RNA delivery platform has not been identified. In this work, we have developed a new class of RNA-delivery vehicle called "Gelasomes," using an incongruous combination of gelatin and lipidoid to exploit each material's unique properties while overcoming their inherent limitations. The low in vivo toxicity of Gelasomes is attributed to the exterior gelatin layers that shield the exposure of cationic lipidoid-siRNA clusters and yet present a biocompatible surface. Indeed, toxicity studies in mice indicate that repeated administration of Gelasomes (up to 48 mg/kg BW) is well-tolerated with no notable changes in body weight, hematology, or serum chemistry. Interestingly, the gelatin outer layer efficiently protects siRNA from serum degradation (48 h), preserving its functionality beyond two months of storage. Notably, Gelasomes possess dual siRNA conjugation modes, i.e., electrostatic binding with lipidoid core and covalent attachment to gelatin surface. The bivalency coupled with lipidoids' high transfection efficiency rendered Gelasomes with remarkably high gene silencing efficiency (>90 %) at very low treatment doses in vitro (40 μg/mL). In vivo studies further confirmed the high gene silencing ability of Gelasomes in non-small cell lung tumor mouse models. This new platform is tunable on all fronts: size, degree of surface coating, and biomolecule functionalization. Truncating the lipidoid C14-tail to a C8-tail yielded Gelasomes of reduced size. As lipidoids with different carbon lengths are synthesizable, we can develop a library of Gelasomes with different sizes. The surface coating with less gelatin resulted in high transfection efficiency at low doses of Gelasomes. The structure of Gelasomes offers chemical handles to couple target-specific molecules like antibodies to tune their properties for efficient biological application.